Diurnal Group PLC (LON:DNL)‘s stock had its “buy” rating reaffirmed by stock analysts at Numis Securities Ltd in a research note issued to investors on Wednesday. They currently have a GBX 187 ($2.31) price objective on the stock. Numis Securities Ltd’s price objective suggests a potential upside of 31.23% from the stock’s current price.

Diurnal Group PLC (LON:DNL) traded down 1.75% on Wednesday, hitting GBX 140.00. 35,000 shares of the stock were exchanged. The company has a 50-day moving average price of GBX 142.25 and a 200-day moving average price of GBX 145.62. The firm’s market cap is GBX 73.09 million. Diurnal Group PLC has a 52-week low of GBX 140.00 and a 52-week high of GBX 155.00.

Diurnal Group PLC Company Profile

Diurnal Group plc is a United Kingdom-based specialty pharmaceutical company. The Company targets patient needs in chronic endocrine (hormonal) diseases, such as congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. The Company has two products in late-stage clinical development targeting adrenal disease: Chronocort and Infacort.

Receive News & Ratings for Diurnal Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.